Lapatinib Plus Capecitabine

Phase 2Small molecule

Lapatinib Plus Capecitabine is one of 66 small molecule programs targeting Esophageal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerActive, not recruiting

Breast CancerActive, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Tecentriq

Roche

Preclinical

36 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

MS Contin

Merck & Co.

Preclinical

2 6

Lapatinib Plus Capecitabine

GSK

Phase 2

2 7

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 8

Nubain

AAultman Health Foundation

Preclinical

1 9

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—10

Zoladex

Luye Pharma Group Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03080805·240 enrolled

Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients

Completed· GSK logo

GSK··NCT01782651·1 enrolled

Esophageal Cancer1 trial

Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer

Terminated·NNational Center for Tumor Diseases, Heidelberg·Phase 2·NCT01145404·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Lapatinib Plus Capecitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lapatinib Plus Capecitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lapatinib Plus Capecitabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

Lapatinib Plus Capecitabine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer2 trials

Esophageal Cancer1 trial

References

Drug Info

Quick Facts

Related News